Inventor · disambiguated record
Jill Wood
Also filed as: WOOD JILL · WOOD JILL E · WOOD JILL E G · WOOD JILL ELIZABETH
24 granted patents·35 pending applications·750 citations·filing 1982–2022
97Inventor score
Top patents by PatentIndex Score
59 records- 0197US7235576B1Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitorsBAYER PHARMACEUTICALS CORP·Filed 2002·Granted Jun 26, 2007·94 cites·47 claims
- 0296US7897623B2ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitorsBAYER HEALTHCARE LLC·Filed 2007·Granted Mar 1, 2011·35 cites·8 claims
- 0396US7625915B2Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureasBAYER HEALTHCARE LLC·Filed 2007·Granted Dec 1, 2009·33 cites·1 claims
- 0496US7528255B2Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitorsBAYER PHARMACEUTICALS CORP·Filed 2002·Granted May 5, 2009·35 cites·15 claims
- 0596US7351834B1ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitorsBAYER PHARMACEUTICALS CORP·Filed 2000·Granted Apr 1, 2008·64 cites·41 claims
- 0696US6187799B1Inhibition of raf kinase activity using aryl ureasONYX PHARMACEUTICALS·Filed 1998·Granted Feb 13, 2001·118 cites·18 claims
- 0794US8841330B2Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitorsRIEDL BERND·Filed 2012·Granted Sep 23, 2014·12 cites·14 claims
- 0894US7329670B1Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureasBAYER PHARMACEUTICALS CORP·Filed 1999·Granted Feb 12, 2008·76 cites·7 claims
- 0994US5789434ADerivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitorsBAYER AG·Filed 1995·Granted Aug 4, 1998·49 cites·10 claims
- 1092US8124630B2ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitorsRIEDL BERND·Filed 2001·Granted Feb 28, 2012·27 cites·16 claims
- 1191US7371763B2Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureasBAYER PHARMACEUTICALS CORP·Filed 2005·Granted May 13, 2008·17 cites·37 claims
- 1287US8466283B2Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisHENTEMANN MARTIN·Filed 2007·Granted Jun 18, 2013·19 cites·47 claims
- 1386USRE46856ESubstituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisBAYER IP GMBH·Filed 2007·Granted May 22, 2018·9 cites·57 claims
- 1486US7517880B2Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureasBAYER PHARMACEUTICALS CORP·Filed 2002·Granted Apr 14, 2009·25 cites·21 claims
- 1586US6784167B217-beta-hydroxysteroid dehydrogenase-II inhibitorsBAYER PHARMACEUTICALS CORP·Filed 2001·Granted Aug 31, 2004·35 cites·17 claims
- 1685US6900205B21,8-Naphthyridine derivatives and their use to treat diabetes and related disordersBAYER PHARMACEUTICALS CORP·Filed 2002·Granted May 31, 2005·19 cites·36 claims
- 1784US7928239B2Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureasBAYER HEALTHCARE LLC·Filed 2001·Granted Apr 19, 2011·15 cites·18 claims
- 1879US8859572B2Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesisHENTEMANN MARTIN F·Filed 2009·Granted Oct 14, 2014·9 cites·16 claims
- 1977US5854277AThiophenebutanoic acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Dec 29, 1998·13 cites·14 claims
- 2076US7109196B21,8 Naphthyridine derivatives and their use to treat diabetes and related disordersBAYER PHARMACEUTICALS CORP·Filed 2004·Granted Sep 19, 2006·7 cites·20 claims
- 2171US5874473ASubstituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Feb 23, 1999·9 cites·16 claims
- 2267US2010063088A1Raf Kinase InhibitorsWOOD JILL E·Filed 2009·Application pending·0 cites
- 2365US2008032979A1Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease InhibitorsRIEDL BERND·Filed 2007·Application pending·0 cites
- 2463US2008153823A1Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase InhibitorsRIEDL BERND·Filed 2007·Application pending·0 cites
- 2561US2008300281A1Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic UreasDUMAS JACQUES·Filed 2008·Application pending·0 cites
- 2661US2009118268A1OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORSRIEDL BERND·Filed 2008·Application pending·0 cites
- 2760US6166082ASubstituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1998·Granted Dec 26, 2000·23 cites·18 claims
- 2860US2012178780A1Raf kinase inhibitorsWOOD JILL E·Filed 2012·Application pending·0 cites
- 2959US2005256174A1Raf kinase inhibitorsWOOD JILL E·Filed 2005·Application pending·0 cites
- 3059US2006189609A11, 8-Naphthyridine derivatives and their use to treat diabetes and related disordersBAYER PHARMACEUTICALS CORP·Filed 2006·Application pending·0 cites
- 3159US2008194580A1Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl UreasDUMAS JACQUES·Filed 2007·Application pending·0 cites
- 3259US2007244120A1Inhibition of raf kinase using substituted heterocyclic ureasDUMAS JACQUES·Filed 2007·Application pending·0 cites
- 3358US2024043473A1Nootropic peptides for treating lysosomal storage diseasesPHOENIX NEST INC·Filed 2022·Application pending·0 cites
- 3458US2009093526A1Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureasMILLER SCOTT·Filed 2007·Application pending·0 cites
- 3557US2014329866A1Omega-carboxyarl substituted diphenyl ureas as raf kinase inhibitorsRIEDL BERND·Filed 2014·Application pending·0 cites
- 3657US2001027202A1Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitorsFiled 2001·Application pending·0 cites
- 3755US5861428ASubstituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Jan 19, 1999·3 cites·16 claims
- 3855US2012046290A1Inhibition of p38 kinase activity using substituted heterocyclic ureasDUMAS JACQUES·Filed 2007·Application pending·0 cites
- 3953US2012129893A1Inhibition Of Raf Kinase Using Substituted Heterocyclic UreasDUMAS JACQUES·Filed 2012·Application pending·0 cites
- 4053US2013261113A1Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisBAYER IP GMBH·Filed 2013·Application pending·0 cites
- 4153US2008108672A1Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase InhibitorsRIEDL BERND·Filed 2007·Application pending·0 cites
- 4252US2008269265A1Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl UreasMILLER SCOTT·Filed 2008·Application pending·0 cites
- 4352US2012270878A1Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureasMILLER SCOTT·Filed 2012·Application pending·0 cites
- 4450US2001016659A1Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitorsFiled 2001·Application pending·0 cites
- 4550US2003105091A1Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitorsFiled 2002·Application pending·0 cites
- 4650US2001034447A1Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitorsFiled 2001·Application pending·0 cites
- 4750US2002042517A1Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitorsBAYER AG·Filed 2001·Application pending·0 cites
- 4849US2001011135A1Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitorsFiled 2001·Application pending·0 cites
- 4949US2001011136A1omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitorsFiled 2001·Application pending·0 cites
- 5048US2002137774A1Carboxyaryl substituted diphenyl ureas as raf kinase inhibitorsBAYER AG·Filed 2001·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →